Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.…
Milestone Pharmaceuticals (MIST) Stock Sees Fair Value Cut As Cardamyst Launch Concerns Persist
Milestone Pharmaceuticals (NASDAQ: MIST) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 38 employees.
The shares were at 0.3711 USD on 20 November 2026, down 78.3% over 52 weeks. Its 52-week range is 0.3620 USD to 3.060 USD: the price is 87.9% below the high and 2.5% above the low.
Its market capitalisation is 46.20M USD.
Milestone Pharmaceuticals reports return on equity of -151.0%.
It holds more cash than debt, a net cash position of 1.59M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 19 March 2027.